PATH - Institutional investors load up on 3M and UiPath stock
2024-04-15 16:42:52 ET
Institutional investors loaded up on shares of 3M Co (NYSE: MMM) and UiPath Inc (NYSE: PATH) in the fourth quarter. Shares of both are still down for the year at writing.
Ingalls & Snyder bought 3M stock in Q4
Ingalls & Snyder LLC bought another 177 shares of in Q4 that increased its stake in the multinational conglomerate by about 7.7%.
The institutional investor now owns a total of 2,490 shares of 3M.
Watch here: https://www.youtube.com/embed/OvQmZ6YFZrQ?feature=oembedUpdate from Ingalls & Snyder arrives a couple weeks after Solventum – a healthcare spinoff of the manufacturing giant started trading on the New York Stock Exchange as Invezz reported here .
3M stock hasn’t performed all that well over the past twelve months but it does pay a rather lucrative dividend yield of 6.62% at writing.
Bleakley Financial bought UiPath stock in Q4
Also on Monday, Bleakley Financial Group LLC said it bought 598 shares of UiPath in the fourth quarter.
The institutional investor now owns a total of 12,691 shares of that pegs its stake in the robotic process automation software company at about 4.9%.
Two fascinating paradoxes in enterprise software today: UiPath & Splunk.
— Aditya Naganath (@anaganath) April 11, 2024
Both have solid financials and continue to grow well. Yet they both:
1. aren't loved by customers
2. are quite clearly facing an innovator's dilemma.
Last week, analysts at KeyBanc Capital initiated UiPath stock with an “overweight” rating. Their $27 price objective suggests a whopping 35% upside as the New York listed firm continues to tap on artificial intelligence and expand its product portfolio.
KeyBanc drove optimism from a surprise profit that reported for its fourth financial quarter in March. UiPath shares are currently down more than 25% versus their year-to-date high.
The post Institutional investors load up on 3M and UiPath stock appeared first on Invezz